UPLC Separation Intergrates into Mass Spectrometers
UPLC Separation Intergrates into Mass Spectrometers
The new ionKey/MS System from Waters provides sensitivity, robustness, and ease-of-use out of mass spectrometry for applications ranging from bioanalyses to pharmacokinetic studies. Intended for use with Waters ACQUITY UPLC M-Class System and Xevo TQ-S Mass Spectrometer, the Waters ionKey/MS System integrates a UPLC separation into the mass spectrometer allowing scientists to achieve enhanced separation and detection of compounds, the company reports.
The ionKey/MS System’s iKey Microfluidic Separation Device contains fluidic connections, electronics, ESI interface, column heater, eCord Intelligent Chip Technology, and 1.7-micron UPLC grade particles inside a 150-micron I.D. channel to perform numerous UPLC separations without a degradation in performance. This plug-and-play design eliminates user-made connections, increasing data quality for scientists.
According to the company, ionKey/MS significantly reduces the amount of solvent consumed compared to 2.1-mm I.D. scale analyses, which results in lower solvent costs, reduced storage and disposal costs, and a more sustainable workflow for the environment.
Waters
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
